These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38090751)

  • 1. Native Mass Spectrometry: Insights and Opportunities for Targeted Protein Degradation.
    Sternicki LM; Poulsen SA
    Anal Chem; 2023 Dec; 95(51):18655-18666. PubMed ID: 38090751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Native mass spectrometry of complexes formed by molecular glues reveals stoichiometric rearrangement of E3 ligases.
    Jackson C; Beveridge R
    Analyst; 2024 May; 149(11):3178-3185. PubMed ID: 38639441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Native mass spectrometry interrogation of complexes formed during targeted protein degradation.
    Ahmed IMM; Beveridge R
    Rapid Commun Mass Spectrom; 2023 Nov; 37(22):e9604. PubMed ID: 37817340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advancement of targeted protein degradation strategies as therapeutics for undruggable disease targets.
    Kannan MP; Sreeraman S; Somala CS; Kushwah RB; Mani SK; Sundaram V; Thirunavukarasou A
    Future Med Chem; 2023 May; 15(10):867-883. PubMed ID: 37254917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Native Mass Spectrometry Can Effectively Predict PROTAC Efficacy.
    Beveridge R; Kessler D; Rumpel K; Ettmayer P; Meinhart A; Clausen T
    ACS Cent Sci; 2020 Jul; 6(7):1223-1230. PubMed ID: 32724856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ligandability of E3 Ligases for Targeted Protein Degradation Applications.
    Belcher BP; Ward CC; Nomura DK
    Biochemistry; 2023 Feb; 62(3):588-600. PubMed ID: 34473924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanistic and Structural Features of PROTAC Ternary Complexes.
    Casement R; Bond A; Craigon C; Ciulli A
    Methods Mol Biol; 2021; 2365():79-113. PubMed ID: 34432240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
    Ishida T; Ciulli A
    SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redefining the Scope of Targeted Protein Degradation: Translational Opportunities in Hijacking the Autophagy-Lysosome Pathway.
    Cassidy K; Zhao H
    Biochemistry; 2023 Feb; 62(3):580-587. PubMed ID: 34569233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Translation of Targeted Protein Degraders.
    Kong NR; Jones LH
    Clin Pharmacol Ther; 2023 Sep; 114(3):558-568. PubMed ID: 37399310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biophysical and Computational Approaches to Study Ternary Complexes: A 'Cooperative Relationship' to Rationalize Targeted Protein Degradation.
    Ward JA; Perez-Lopez C; Mayor-Ruiz C
    Chembiochem; 2023 May; 24(10):e202300163. PubMed ID: 37018140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Redirecting the specificity of tripartite motif containing-21 scaffolds using a novel discovery and design approach.
    VanDyke D; Xu L; Sargunas PR; Gilbreth RN; Baca M; Gao C; Hunt J; Spangler JB
    J Biol Chem; 2023 Dec; 299(12):105381. PubMed ID: 37866632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expanding PROTACtable genome universe of E3 ligases.
    Liu Y; Yang J; Wang T; Luo M; Chen Y; Chen C; Ronai Z; Zhou Y; Ruppin E; Han L
    Nat Commun; 2023 Oct; 14(1):6509. PubMed ID: 37845222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advancing targeted protein degradation for metabolic diseases therapy.
    Zhou QQ; Xiao HT; Yang F; Wang YD; Li P; Zheng ZG
    Pharmacol Res; 2023 Feb; 188():106627. PubMed ID: 36566001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of KLHDC2 as an efficient proximity-induced degrader of K-RAS, STK33, β-catenin, and FoxP3.
    Röth S; Kocaturk NM; Sathyamurthi PS; Carton B; Watt M; Macartney TJ; Chan KH; Isidro-Llobet A; Konopacka A; Queisser MA; Sapkota GP
    Cell Chem Biol; 2023 Oct; 30(10):1261-1276.e7. PubMed ID: 37591251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small-Molecule Degraders beyond PROTACs-Challenges and Opportunities.
    Kastl JM; Davies G; Godsman E; Holdgate GA
    SLAS Discov; 2021 Apr; 26(4):524-533. PubMed ID: 33632029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Driving E3 Ligase Substrate Specificity for Targeted Protein Degradation: Lessons from Nature and the Laboratory.
    Cowan AD; Ciulli A
    Annu Rev Biochem; 2022 Jun; 91():295-319. PubMed ID: 35320687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling the CRL4A ligase complex to predict target protein ubiquitination induced by cereblon-recruiting PROTACs.
    Bai N; Riching KM; Makaju A; Wu H; Acker TM; Ou SC; Zhang Y; Shen X; Bulloch DN; Rui H; Gibson BW; Daniels DL; Urh M; Rock BM; Humphreys SC
    J Biol Chem; 2022 Apr; 298(4):101653. PubMed ID: 35101445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting the structural basis of targeted protein degradation by integrating molecular dynamics simulations with structural mass spectrometry.
    Dixon T; MacPherson D; Mostofian B; Dauzhenka T; Lotz S; McGee D; Shechter S; Shrestha UR; Wiewiora R; McDargh ZA; Pei F; Pal R; Ribeiro JV; Wilkerson T; Sachdeva V; Gao N; Jain S; Sparks S; Li Y; Vinitsky A; Zhang X; Razavi AM; Kolossváry I; Imbriglio J; Evdokimov A; Bergeron L; Zhou W; Adhikari J; Ruprecht B; Dickson A; Xu H; Sherman W; Izaguirre JA
    Nat Commun; 2022 Oct; 13(1):5884. PubMed ID: 36202813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.
    Setia N; Almuqdadi HTA; Abid M
    Eur J Med Chem; 2024 Feb; 265():116041. PubMed ID: 38199162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.